A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium

Journal of Drugs in Dermatology

Volumn 12, Issue 6, 2013, Pages 658-663

  Leyden, James J ^a,b   Bruce, Suzanne ^c   Lee, Chai Sue ^d   Ling, Mark ^e   Sheth, Pranav B ^f   Stewart, Daniel M ^g   Werschler, William P ^h,i   Gilbert, Richard D ^j   Kircik, Leon ^k,l,m  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b KGL Inc   (United States)

^c Center for Skin Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MedaPhase Inc   (United States)

^f TriHealth   (United States)

^g Maryland Laser Skin and Vein Institute   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ Premier Clinical Research   (United States)

^j TKL RESEARCH INC   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MOUNT SINAI MEDICAL CENTER   (United States)

^m Physicians Skin Care PLLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; UNCLASSIFIED DRUG; WC 2055;

ACNE VULGARIS; ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CANDIDIASIS; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INVESTIGATOR GLOBAL ASSESSMENT SCORE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; NAUSEA; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SCORING SYSTEM; TABLET FORMULATION; THORAX DISEASE; TREATMENT OUTCOME; VAGINITIS;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXYCYCLINE; FACE; FEMALE; HUMANS; INFLAMMATION; LOGISTIC MODELS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84878666727     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1-37.
2. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1-50.
3. Stewart DM, Torok HM, Weiss JS, Plott RT; Solodyn Phase 2 Study Group. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006;78(4 Suppl):11-20. (Pubitemid 44720405)
4. Bretz F, Dette H, Pinheiro JC. Practical considerations for optimal designs in clinical dose finding studies. Stat Med. 2010;29:731-742.
5. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER), September 2005. Guidance for Industry. Acne Vulgaris: Developing Drugs for Treatment. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071292.pdf. Accessed December 12, 2012.
6. Fleischer AB Jr, Dinehart S, Stough D, Plott RT; Solodyn Phase 2 Study Group; Solodyn Phase 3 Study Group. Safety and efficacy of a new extended-release formulation of minocycline. Cutis. 2006;78(4 Suppl):21-31. (Pubitemid 44720406)
7. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464. (Pubitemid 36427610)